These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 25783505)

  • 1. Thymoma treated with 177Lu DOTATATE induction and maintenance PRRT.
    Makis W; McCann K; McEwan AJ
    Clin Nucl Med; 2015 May; 40(5):e278-81. PubMed ID: 25783505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver and bone metastases from small bowel neuroendocrine tumor respond to 177Lu-DOTATATE induction and maintenance therapies.
    Makis W; McCann K; Buteau FA; McEwan AJ
    Clin Nucl Med; 2015 Feb; 40(2):162-5. PubMed ID: 25243941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete Resolution of Neuroendocrine Tumor Soft Tissue Metastases After 177Lu DOTATATE PRRT Induction and Maintenance Therapy.
    Makis W; McCann K; Buteau FA; McEwan AJ
    Clin Nucl Med; 2015 Aug; 40(8):663-6. PubMed ID: 25546219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagonoma Pancreatic Neuroendocrine Tumor Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy.
    Makis W; McCann K; Riauka TA; McEwan AJ
    Clin Nucl Med; 2015 Nov; 40(11):877-9. PubMed ID: 26204206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extraventricular neurocytoma treated with 177Lu DOTATATE PRRT induction and maintenance therapies.
    Makis W; McCann K; McEwan AJ
    Clin Nucl Med; 2015 Mar; 40(3):234-6. PubMed ID: 25608145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC.
    Severi S; Sansovini M; Ianniello A; Bodei L; Nicolini S; Ibrahim T; Di Iorio V; D'Errico V; Caroli P; Monti M; Paganelli G
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1955-63. PubMed ID: 26112388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?
    Esser JP; Krenning EP; Teunissen JJ; Kooij PP; van Gameren AL; Bakker WH; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1346-51. PubMed ID: 16847654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orbital Metastases of Neuroendocrine Tumors Treated With 177Lu-DOTATATE PRRT or 131I-MIBG Therapies.
    Makis W; McCann K; McEwan AJ
    Clin Nucl Med; 2016 Feb; 41(2):137-41. PubMed ID: 26447382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Esthesioneuroblastoma (olfactory neuroblastoma) treated with 111In-octreotide and 177Lu-DOTATATE PRRT.
    Makis W; McCann K; McEwan AJ
    Clin Nucl Med; 2015 Apr; 40(4):317-21. PubMed ID: 25674857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
    Parghane RV; Talole S; Prabhash K; Basu S
    Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resolution of Hyperreninemia, Secondary Hyperaldosteronism, and Hypokalemia With 177Lu-DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy in a Patient With Pancreatic Neuroendocrine Tumor.
    Makis W; McCann K; Riauka TA; McEwan AJ
    Clin Nucl Med; 2015 Nov; 40(11):880-4. PubMed ID: 26359564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of peptide receptor radionuclide therapy (PRRT) with tandem isotopes - [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on [18F]FDG PET/CT qualification in Polish multicentre experience - do we need [18F]FDG PET/CT for qualification to PRRT?
    Zemczak A; Kołodziej M; Gut P; Królicki L; Kos-Kudła B; Kamiński G; Ruchała M; Pawlak D; Kunikowska J
    Endokrynol Pol; 2020; 71(3):240-248. PubMed ID: 32293704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retreatment with peptide receptor radionuclide therapy in patients with progressing neuroendocrine tumours: efficacy and prognostic factors for response.
    Vaughan E; Machta J; Walker M; Toumpanakis C; Caplin M; Navalkissoor S
    Br J Radiol; 2018 Nov; 91(1091):20180041. PubMed ID: 29513039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medullary thyroid carcinoma (MTC) treated with 177Lu-DOTATATE PRRT: a report of two cases.
    Makis W; McCann K; McEwan AJ
    Clin Nucl Med; 2015 May; 40(5):408-12. PubMed ID: 25674858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatopulmonary Shunt Reduction With 177Lu-DOTATATE Therapy.
    Acar E; Çapa Kaya G; Durak H
    Clin Nucl Med; 2016 Nov; 41(11):866-871. PubMed ID: 27607172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function.
    Ranade R; Basu S
    J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac metastases of neuroendocrine tumors treated with 177Lu DOTATATE peptide receptor radionuclide therapy or 131I-MIBG therapy.
    Makis W; McCann K; Bryanton M; McEwan AJ
    Clin Nucl Med; 2015 Dec; 40(12):962-4. PubMed ID: 26359563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete Remission of Metastatic Neuroendocrine Paragastric Carcinoma After "Neoadjuvant" Peptide Receptor Radionuclide Therapy and Surgery.
    Schmidt MC; Uhrhan K; Fischer T; Schmitz S; Markiefka B; Drzezga A; Stippel D
    Clin Nucl Med; 2015 Aug; 40(8):667-9. PubMed ID: 26053706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rhabdoid papillary meningioma treated with 177Lu DOTATATE PRRT.
    Makis W; McCann K; McEwan AJ
    Clin Nucl Med; 2015 Mar; 40(3):237-40. PubMed ID: 25608146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additional hepatic
    Braat AJAT; Kwekkeboom DJ; Kam BLR; Teunissen JJM; de Herder WW; Dreijerink KMA; van Rooij R; Krijger GC; de Jong HWAM; van den Bosch MAAJ; Lam MGEH
    BMC Gastroenterol; 2018 Jun; 18(1):84. PubMed ID: 29902988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.